Novel approvals (N = 156) | Number (%) |
---|---|
FDA review pathwaya | |
Priority | 16 (10) |
Standard | 140 (90) |
Life-sustaining designationa | |
Life-sustaining | 84 (54) |
Non-life-sustaining | 72 (46) |
Implantable designationa | |
Implantable | 123 (79) |
Non-implantable | 33 (21) |
Combination producta | |
No | 127 (81) |
Yes | 29 (19) |
Company management | |
Public | 96 (62) |
Private | 60 (38) |